N-(2-methylpropyl)ethanesulfonamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: N-(2-methylpropyl)ethanesulfonamide
• 化学式: C₆H₁₅NO₂S
• mdl: MFCD03385151
• 分子量: 165.26
• InChiKey: BRQMYUTYTCOSRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Diaryl piperidines as CB1 modulators
  申请人：Scott D. Jack

  公开号：US20070203183A1

  公开（公告）日：2007-08-30

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome (e.g., obesity, waist circumference, lipid profile, and insulin sensitivity), neuroinflammatory disorders, cognitive disorders, psychosis, addictive behavior, gastrointestinal disorders, and cardiovascular conditions.

  具有通式（I）的一种化合物，或其药学上可接受的盐、溶剂合物或酯，可用于治疗代谢综合征（例如肥胖、腰围、脂质谱和胰岛素敏感性）、神经炎症性疾病、认知障碍、精神病、成瘾行为、胃肠道疾病和心血管疾病等疾病、疾病或症状。
• HSP90-TARGETED CARDIAC IMAGING AND THERAPY
  申请人：MEMORIAL SLOAN-KETTERING CANCER CENTER

  公开号：US20160015837A1

  公开（公告）日：2016-01-21

  The present invention provides new methods for cardiac imaging and related medical applications thereof. In some embodiments, the present invention provides a method for the diagnosis of cardiovascular diseases, conditions, or disorders. In some embodiments, the present invention provides a method for the treatment or prevention of cardiovascular diseases, conditions, or disorders. In some embodiments, the present invention provides methods for monitoring the effect of cancer treatment on the heart, and/or methods for monitoring a cancer treatment regimen. In some embodiments, the present invention provides a method for selecting subjects for a test or treatment. In some embodiments, the present invention provides a method for determining the dosage of a drug. In some embodiments, the present invention provides methods for determining the risk of a cardiovascular disease, for assessing risk of a cardiovascular disease, and/or for determining the risk of heart attack.

  本发明提供了心脏成像的新方法及相关的医疗应用。在某些实施例中，本发明提供了一种用于诊断心血管疾病、症状或障碍的方法。在某些实施例中，本发明提供了一种用于治疗或预防心血管疾病、症状或障碍的方法。在某些实施例中，本发明提供了用于监测癌症治疗对心脏的影响的方法，和/或用于监测癌症治疗方案的方法。在某些实施例中，本发明提供了一种用于选择测试对象或治疗的方法。在某些实施例中，本发明提供了一种确定药物剂量的方法。在某些实施例中，本发明提供了用于确定心血管疾病风险、评估心血管疾病风险和/或确定心脏病发风险的方法。
• [EN] HSP90-TARGETED CARDIAC IMAGING AND THERAPY<br/>[FR] IMAGERIE CARDIAQUE À CIBLAGE HSP90 ET TRAITEMENT ASSOCIÉ
  申请人：SLOAN KETTERING INST CANCER

  公开号：WO2014144715A1

  公开（公告）日：2014-09-18

  The present invention provides new methods for cardiac imaging and related medical applications thereof. In some embodiments, the present invention provides a method for the diagnosis of cardiovascular diseases, conditions, or disorders. In some embodiments, the present invention provides a method for the treatment or prevention of cardiovascular diseases, conditions, or disorders. In some embodiments, the present invention provides methods for monitoring the effect of cancer treatment on the heart, and/or methods for monitoring a cancer treatment regimen. In some embodiments, the present invention provides a method for selecting subjects for a test or treatment. In some embodiments, the present invention provides a method for determining the dosage of a drug. In some embodiments, the present invention provides methods for determining the risk of a cardiovascular disease, for assessing risk of a cardiovascular disease, and/or for determining the risk of heart attack.

  本发明提供了新的心脏成像方法及其相关医疗应用。在某些实施例中，本发明提供了一种诊断心血管疾病、病况或障碍的方法。在某些实施例中，本发明提供了一种治疗或预防心血管疾病、病况或障碍的方法。在某些实施例中，本发明提供了监测癌症治疗对心脏影响的方法，和/或监测癌症治疗方案的方法。在某些实施例中，本发明提供了选择测试或治疗对象的方法。在某些实施例中，本发明提供了确定药物剂量的方法。在某些实施例中，本发明提供了确定心血管疾病风险、评估心血管疾病风险和/或确定心脏病发作风险的方法。
• [EN] HSP90-TARGETED INFLAMMATION AND INFECTION IMAGING AND THERAPY<br/>[FR] IMAGERIE ET THÉRAPIE D'UNE INFLAMMATION ET D'UNE INFECTION CIBLANT HSP90
  申请人：SLOAN KETTERING INST CANCER

  公开号：WO2016044629A1

  公开（公告）日：2016-03-24

  The present invention provides new methods for inflammation and infection imaging and related medical applications thereof. In some embodiments, the present invention provides a method for the diagnosis of inflammation and/or infection. In some embodiments, the present invention provides a method for the treatment or prevention of inflammation and/or infection. In some embodiments, the present invention provides methods for monitoring the effect of inflammation and/or infection treatment, and/or methods for monitoring an inflammation and/or infection treatment regimen. In some embodiments, the present invention provides a method for selecting subjects for an inflammation and/or infection treatment. In some embodiments, the present invention provides a method for determining the dosage of a drug for the treatment of inflammation and/or infection.

  本发明提供了新的炎症和感染成像方法及其相关医学应用。在某些实施例中，本发明提供了一种用于炎症和/或感染诊断的方法。在某些实施例中，本发明提供了一种用于炎症和/或感染治疗或预防的方法。在某些实施例中，本发明提供了用于监测炎症和/或感染治疗效果的方法，以及/或用于监测炎症和/或感染治疗方案的方法。在某些实施例中，本发明提供了一种用于选择炎症和/或感染治疗对象的方法。在某些实施例中，本发明提供了一种用于确定治疗炎症和/或感染药物剂量的方法。
• NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO
  申请人：DYCK Brian

  公开号：US20110166116A1

  公开（公告）日：2011-07-07

  New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein R 1 , R 2 , R 3 , n, p, q, and Ar are as defined herein, including stereoisomers, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising a compound of this invention, as well as methods relating to the use thereof in a patient in need thereof.

  本发明披露了一种新化合物，其在治疗患者的各种代谢相关疾病方面具有用途。本发明的化合物具有结构（I）：其中R1、R2、R3、n、p、q和Ar的定义如本文所述，包括立体异构体和药物可接受的盐。本发明还披露了包括本发明化合物的制药组合物，以及与在需要时使用该化合物的相关方法。